Notice of AGM

19 May 2016

Cyprotex PLC

("Cyprotex" or the "Company" or the "Group")

Publication of Annual Report & Accounts 2015

 & Notice of AGM

Cyprotex PLC announces that its 2015 Annual Report and Accounts for the year ending 31 December 2015, together with the Notice of the Annual General Meeting and associated proxy form will today be posted to shareholders.

The 2015 Annual Report and Accounts are available from the Company's website, www.cyprotex.com 

Cyprotex PLC's Annual General Meeting will be held on Thursday 23 June 2015 at 10.00 a.m. at the offices of N+1 Singer Advisory LLP, One Bartholomew Lane, London EC2N 2AX .

For further information:

Notes to Editors:

Cyprotex PLC

Cyprotex is quoted on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1400 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™ and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com